MedRhythms Expands Horizons with New CCO Joel Behnke and Exciting Publications
MedRhythms Welcomes Joel Behnke as Chief Commercial Officer
MedRhythms, Inc., a pioneering company in the neurotherapeutic sector, has announced the significant appointment of Joel Behnke as its Chief Commercial Officer (CCO). With over 20 years of experience in the medical device industry, particularly in rehabilitation, Behnke's leadership role is expected to accelerate MedRhythms' sales and marketing efforts, primarily focusing on their flagship product, InTandem—a cutting-edge neurorehabilitation system tailored for individuals suffering from chronic stroke-induced gait impairments.
A Seasoned Executive Joins Forces with MedRhythms
According to Brian Harris, Co-Founder and CEO of MedRhythms, Behnke's extensive background positions him perfectly to lead the company's commercial growth initiatives. Harris emphasized, "Joel has a strong track record of demonstrated success in scaling medical devices in rehabilitation, specializing in improving mobility in neurologic injury and disease states. His deep domain expertise, along with a data-driven leadership style, makes him the ideal candidate to spearhead our commercial ambitions."
Before joining MedRhythms, Behnke held a prominent role as Vice President of Sales, Marketing & Strategy at Bioventus, where he notably led the divestiture of the Advanced Rehabilitation Division. His successful management in strategic leadership and operational excellence suggests he will bring valuable insight as MedRhythms continues to innovate in the healthcare space.
MedRhythms' Commitment to Innovation
In his first statement as CCO, Behnke expressed his enthusiasm about the potential of MedRhythms' product suite, stating, "The innovative pipeline of MedRhythms holds immense potential to redefine care standards for patients with chronic diseases experiencing mobility impairments. I look forward to collaborating with this talented management team to drive our commercial initiatives."
In addition to this appointment, MedRhythms unveiled two new publications aiming to address significant gaps in stroke rehabilitation practices. The publications stand to assist healthcare professionals in understanding the effectiveness and economic value of the InTandem system.
The first publication, titled Multidisciplinary Delphi Panel on Rehabilitation Approaches and Unmet Needs for Chronic Stroke Walking Impairment and the Role of Rhythmic Auditory Stimulation, was released in Cureus in August 2024. This study involved a panel of eight experts who established consensus on current practices and identified unmet needs in stroke rehabilitation, particularly emphasizing the role of rhythmic auditory stimulation (RAS) to improve gait rehabilitation.
The second publication, which provides a one-year budget impact analysis of InTandem, was published in the Journal of Comparative Effectiveness Research in September 2024. According to this analysis, introducing InTandem is projected to yield significant cost savings of approximately $439,954 over one year from a payer perspective, thus highlighting not only its therapeutic value but also its financial viability.
Future Directions for MedRhythms
As Behnke takes the helm of MedRhythms’ commercial endeavors, he emphasized the importance of these studies alongside the recent determination from the Centers for Medicare and Medicaid Services (CMS) regarding InTandem payments. "These studies and the positive payment determinations will serve as critical tools as we forge connections with patients, healthcare providers, and payers to drive the expansion of our initiatives," he remarked.
MedRhythms remains focused on the development of cutting-edge neurotherapeutics designed to enhance mobility and related functional outcomes. The company continuously blends technology and advanced neuroscience techniques to address various neurological conditions, including stroke, multiple sclerosis, and Parkinson's disease.
With Behnke at the forefront of commercial strategies, MedRhythms is poised for growth, heralding a new era of innovation and care for patients with mobility challenges. The company's efforts to redefine rehabilitation standards through technology offer optimism for those affected by chronic conditions, marking a transformative step in medical care.
For more insights, explore MedRhythms’ offerings at www.medrhythms.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.